1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Luye Pharma Group Ltd.

Luye Pharma Group Ltd.

1.59
HKD
+0.01
(+0.63%)
10.94BMarket Cap
Mar 31Next Earn
Luye Pharma Group Ltd.
HKEX:2186
(Hong Kong Exchange)

Recent

price

1.59

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.94
2.72
3.6
5.1
0.85
0.77
0.88
1.17
1.61
1.98
1.74
1.51
1.72
1.65
1.61
1.62
- -
Revenue per Share
0.25
0.28
0.31
0.63
0.2
0.23
0.27
0.3
0.41
0.44
0.22
-0.04
0.17
0.14
0.13
0.16
- -
Basic EPS, GAAP
0.28
0.23
-0.03
0.34
0.07
0.06
0.08
0.1
-0.45
-0.51
-0.15
-0.39
0.14
0.12
-0.41
0.2
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.03
0.07
0.09
0.12
0.06
- -
- -
- -
- -
- -
- -
Dividend per Share
2
2.29
2.59
0.53
1.48
1.71
1.94
2.11
2.38
2.82
2.52
2.48
2.96
3.33
3.76
4.02
4.02
Book Value per Share
0.88
1.21
1.04
0.39
1.33
1.56
1.38
1.53
0.71
1.01
0.66
0.6
0.93
1.37
1.74
2.06
2.06
Tangible Book Value per Share
493
493
493
493
2,995
3,321
3,321
3,258
3,208
3,203
3,187
3,445
3,481
3,728
3,762
3,896
3,878
Basic Weighted Avg Shares
955
1,341
1,774
2,515
2,544
2,563
2,918
3,815
5,173
6,358
5,540
5,200
5,982
6,143
6,061
6,308
- -
Sales/Revenue/Turnover
16.97
15.06
12.14
16.45
28.49
32.42
31.35
28.59
29.32
27.37
21.94
5.44
15.95
16.75
21.3
19.9
- -
Operating Margin (%)
45
70
79
100
110
115
141
250
317
456
511
582
671
702
791
839
- -
Depreciation Expense
124
136
152
310
606
755
892
981
1,303
1,396
707
-134
605
533
472
619
- -
Net Income, GAAP
22.29
23.04
17.35
14.41
15.31
14.86
8.28
12.16
11.37
17.13
25.36
- -
12.91
23
23.14
25.3
- -
Effective Tax Rate (%)
12.94
10.15
8.55
12.35
23.8
29.44
30.56
25.73
25.19
21.96
12.76
-2.58
10.11
8.67
7.79
9.81
- -
Profit Margin (%)
386
436
39
349
2,638
4,026
2,908
2,641
472
3,819
2,736
3,066
1,299
2,565
2,539
5,297
5,297
Working Capital
30
1
2
9
1
- -
- -
- -
848
4,510
4,339
4,228
2,265
3,228
2,736
2,723
2,723
LT Debt
1,095
1,248
1,404
1,898
5,038
5,800
6,562
6,896
7,934
8,920
8,099
9,114
11,042
13,528
15,754
18,359
18,359
Total Equity
11.08
10.98
10.42
15.01
15.79
15.76
14.85
10.35
11.02
9.01
4.91
- -
4.11
3.74
4.1
3.41
- -
Return on Invested Capital (%)
12.12
9.29
9.08
13.92
15.78
13.01
12.66
11.44
12.19
10.67
5.77
- -
5.35
4.97
3.04
3.88
- -
Return on Capital (%)
13.66
12.88
12.62
20.39
18.14
14.27
14.75
14.87
17.88
16.7
8.41
-1.64
6.48
4.69
3.54
4.09
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
7,585
8,721
6,694
LT Borrowings
2,694
3,112
2,688
LT Finance Leases
42
37
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,762
3,762
3,995
Market Capitalization
7,670
12,290
9,835

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
13,308
15,687
15,233
Cash, Cash Equivalents & STI
6,503
8,833
7,495
Accounts Receivable, Net
2,384
2,886
2,847
Inventories
912
872
957
Total Current Liabilities
10,769
11,939
9,936
Payables & Accruals
- -
- -
- -
ST Debt
7,585
8,721
6,694
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.57%
17.84%
16.54%
Free Cash Flow
-108.87%
-115.52%
-150.65%
Net Income, GAAP
-64.25%
-132.25%
31.12%
Sales/Revenue/Turnover
10.46%
2.87%
4.07%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
6,143
2024
- -
- -
6,061
2025
- -
- -
6,308

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.14
2024
- -
- -
0.13
2025
- -
- -
0.16

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Luye Pharma Group Ltd. Luye Pharma Group Ltd. (2186.HK) is an investment holding company engaged in the research, development, manufacturing, marketing, and sale of innovative pharmaceutical products with a focus on novel drug delivery systems including microspheres, liposomes, and transdermal patches; it also develops new chemical entities and antibody drugs across core therapeutic areas such as central nervous system disorders (including schizophrenia, bipolar disorder, major depressive disorder, Alzheimer's disease psychosis, Parkinson's disease psychosis, and negative schizophrenia symptoms with products like Erzofri (paliperidone palmitate) extended-release injectable suspension, Rykindo (risperidone) extended-release injectable suspension, Ruoxinlin (toludesvenlafaxine hydrochloride sustained-release tablets), Rivastigmine Twice Weekly Transdermal Patch, Jinyouping (rotigotine microspheres for injection), and rotigotine transdermal patch), oncology, cardiovascular, alimentary tract and metabolism, as well as other segments; the company operates over 30 launched products and maintains a pipeline of more than 30 investigational candidates including small-molecule drugs like LY03017 (next-generation 5-HT2AR inverse agonist/5-HT2CR antagonist), LY03015 (VMAT2/Sigma-1R), LY03020 (TAAR1/5-HT2CR), and LY03021 (NET/DAT/GABAAR). Founded in 1994 and headquartered in Yantai, China, with key R&D centers in China, the U.S., and Europe, plus eight GMP-compliant manufacturing facilities worldwide, Luye Pharma conducts business in over 80 countries and regions encompassing major markets like China, the U.S., Europe, and Japan, alongside emerging markets in Asia, Latin America, Africa, and Oceania. Recent developments include FDA clearance in November 2025 for the IND of LY03017 to advance directly to multiple ascending dose trials for Alzheimer's and Parkinson's disease psychosis and negative schizophrenia symptoms; enrollment completion for the Phase III trial of Ruoxinlin for generalized anxiety disorder in August 2025 and first subject dosing in a Phase I trial for LY03021 in China; launch of rotigotine transdermal patch in the UK in April 2025; acquisition of Acino's transdermal patch business in June 2025 to bolster R&D and manufacturing; a July 2024 investment agreement to upgrade oncology R&D through collaborations; and reporting 32% growth in new product sales alongside an upgraded international strategy emphasizing in-house development plus business development partnerships in its 2025 half-year results.